scholarly journals Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages

2018 ◽  
Vol 13 (4) ◽  
pp. 288 ◽  
Author(s):  
Soliman Mohammadi-Samani ◽  
Parisa Ghasemiyeh
Keyword(s):  
Drug Delivery ◽  
Solid Lipid Nanoparticles ◽  
Drug Delivery Systems ◽  
Lipid Nanoparticles ◽  
Delivery Systems ◽  
Nanostructured Lipid Carriers ◽  
Advantages And Disadvantages ◽  
Solid Lipid ◽  
Novel Drug

scholarly journals Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme

Pharmaceutics ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 860
Author(s):  
Raneem Jnaidi ◽  
António José Almeida ◽  
Lídia M. Gonçalves
Keyword(s):  
Drug Delivery ◽  
Glioblastoma Multiforme ◽  
Solid Lipid Nanoparticles ◽  
Drug Delivery Systems ◽  
Drug Carriers ◽  
Lipid Nanoparticles ◽  
Tumor Location ◽  
Delivery Systems ◽  
Nanostructured Lipid Carriers ◽  
Solid Lipid

Glioblastoma multiforme (GBM) is the most common and malignant type of brain tumor. In fact, tumor recurrence usually appears a few months after surgical resection and chemotherapy, mainly due to many factors that make GBM treatment a real challenge, such as tumor location, heterogeneity, presence of the blood-brain barrier (BBB), and others. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) represent the most promising carriers for therapeutics delivery into the central nervous system (CNS) owing to their inherent ability to cross the BBB. In this review, we present the main challenges in GBM treatment, a description of SLNs and NLCs and their valuable role as drug carriers in GBM treatment, and finally, a detailed description of all modification strategies that aim to change composition of SLNs and NLCs to enhance treatment outcomes. This includes modification of SLNs and NLCs to improve crossing the BBB, reduced GBM cell resistance, target GBM cells selectively minimizing side effects, and modification strategies to enhance SLNs and NLCs nose-to-brain delivery. Finally, future perspectives on their use are also be discussed, to provide insight about all strategies with SLNs and NLCs formulation that could result in drug delivery systems for GBM treatment with highly effective theraputic and minimum undesirable effects.

scholarly journals Topical Antiacne Drugs Delivery Systems

2016 ◽  
Vol 10 (1) ◽  
pp. 85-95
Author(s):  
Tesfaye Gabriel
Keyword(s):  
Drug Delivery ◽  
Solid Lipid Nanoparticles ◽  
Drug Delivery Systems ◽  
Topical Therapy ◽  
Topical Administration ◽  
Lipid Nanoparticles ◽  
Delivery Systems ◽  
Solid Lipid ◽  
First Choice ◽  
Novel Drug

Background: Acne vulgaris (commonly called acne) is the most prevalent skin complication of different causes with a higher prevalence in adolescents. Topical administration is used as first-choice therapy in mild acne, whereas for moderate and severe acne, systemic administration is required in addition to topical therapy. Mechanisms by which treatments act are: normalizing shedding into the pore to prevent obstruction, destruction of P.acnes, suppression of inflammation, and hormonal management. Objective: This review focuses on the novel drug delivery systems displaying a strong ground for topical treatment of acne in order to enhance the therapeutic performance of the topical antiacne agents with improved patience compliance and a concomitant reduction in the side effects. Method: This literature review was obtained from electronic search on Pubmed, Google Scholars, Researchgate, Scimago, CABI, DOAJ, CiteFactor, GLOBAL HEALTH, Universal Impact Factor, Hinari among many others and also search was conducted on individual journals and manuals. Conclusion: Amongst various novel drug delivery systems, vesicular carriers like liposomes and niosomes, micro sponges, microemulsions, solid lipid nanoparticles, hydrogels, emulsifier-free formulations, fullerenes and aerosol foams have been reported as novel topical administration of antiacne drugs. Liposomes have been extensively explored and their ability to optimize and improve topical therapy has been proved by several clinical trials. Microemulsions, microsponges, solid lipid nanoparticles and hydrogels also exhibit a tremendous potential for commercialization.

Development of Gel-Core Solid Lipid Nanoparticles as Drug Delivery Systems for Hydrophilic Molecules

2016 ◽  
Vol 12 (5) ◽  
pp. 598-604 ◽  
Author(s):  
Tatiana N. Pashirova ◽  
Tatiana Andreani ◽  
Ana S. Macedo ◽  
Eliana B. Souto ◽  
Lucia Ya. Zakharova
Keyword(s):  
Drug Delivery ◽  
Solid Lipid Nanoparticles ◽  
Drug Delivery Systems ◽  
Lipid Nanoparticles ◽  
Delivery Systems ◽  
Solid Lipid

scholarly journals Solid Lipid Nanoparticles: A Brief Review

2021 ◽  
pp. 368-385
Author(s):  
Amol Giri ◽  
Aijaz Sheikh ◽  
P R Tathe ◽  
G R Sitaphale ◽  
K R Biyani
Keyword(s):  
Drug Delivery ◽  
Solid Lipid Nanoparticles ◽  
Surfactant Solution ◽  
Lipid Nanoparticles ◽  
Drug Bioavailability ◽  
New Approach ◽  
Pharmaceutical Ingredients ◽  
Advantages And Disadvantages ◽  
Solid Lipid ◽  
Novel Drug

In this present review this new approach of solid lipid Nanoparticles (SLNs) is discussed in terms of their aims, advantages, and disadvantages, methods of preparation, characterization and special features. In the state of developments in the research and development of new drug delivery systems have been made in Last decade by resolving various disorders, such as Low Drug Bioavailability and unpredictable gastric emptying era. Most of the active pharmaceutical ingredients are under poor bioavailability and also their solubility. By using the nanotechnology to overcome this problems of novel drug delivery system. The main advantage of nanotechnology i.e. solid lipid Nanoparticles increases the bioavailability and elimination biological half-life of the drugs. Solid lipid Nanoparticles are spherical lipid particles ranging in size from 1 to 1000 nm and are dispersed in water or in aqueous surfactant solution.

scholarly journals A mini-review of Nanocarriers in drug delivery systems Nanocarriers in drug delivery systems

2021 ◽  
Author(s):  
Mahsa Mazdaei ◽  
Kofi Asare-Addo
Keyword(s):  
Drug Delivery ◽  
Gene Delivery ◽  
Cancer Chemotherapy ◽  
Solid Lipid Nanoparticles ◽  
Drug Delivery Systems ◽  
Lipid Nanoparticles ◽  
Delivery Systems ◽  
Therapeutic Gene ◽  
Solid Lipid ◽  
The Past

The application of nanotechnology indrug delivery systems (DDS) has been researched widely and seen an advancementover the past three decades. Since the 1970s, nanoparticles were primarilyutilised in vaccine deliveries and cancer chemotherapy. In more recent years,they have been found to hold promises for broader applications such as inproteins and therapeutic gene delivery systems. To date, there have been only ahandful of nanocarrier-loaded drugs commercialised into the pharmaceuticalmarket. More research is thus needed to facilitate a breakthrough of theseproducts into the current market. This mini-review mainly focuses on four typesof commonly utilised organic nanocarriers including micelles, compactpolymerics, solid-lipid nanoparticles and liposomal vesicles and discusses theprogress and some challenges associated with these nanoparticles (NP). 

SOLID LIPID NANOPARTICLES: EMERGING COLLOIDAL CARRIERS AS OCULAR DRUG DELIVERY SYSTEMS

INDIAN DRUGS ◽  
2013 ◽  
Vol 50 (04) ◽  
pp. 5-25
Author(s):  
N.G.N Swamy ◽  
Z Abbas ◽  
Keyword(s):  
Drug Delivery ◽  
Solid Lipid Nanoparticles ◽  
Drug Delivery Systems ◽  
Critical Evaluation ◽  
Lipid Nanoparticles ◽  
Delivery Systems ◽  
Ocular Drug Delivery ◽  
Eye Drops ◽  
Solid Lipid ◽  
Ocular Bioavailability

Numerous attempts have been made to improve the bioavailability from ocular drug delivery systems and to prolong the residence time of drugs applied topically onto the eye. Conventional ocular drug delivery systems such as eye drops and ointments are inefficient, whereas, systemic administration requires high doses which may result in significant toxicity. Therefore, a need arises to develop novel drug delivery carrier systems capable of increasing ocular bioavailability and decreasing both local and systemic cytotoxicity. Nanotechnology is expected to revolutionize ocular drug delivery. Solid lipid nanoparticles (SLNs) introduced in 1991 represent an alternative carrier system to traditional colloidal carriers, such as emulsions, liposomes and polymeric micro- and nanoparticles. SLNs do not show biotoxicity as they are prepared from physiological lipids and are ideal ocular drug delivery systems as they can enhance the corneal absorption of drugs and improve the ocular bioavailability of both hydrophilic and lipophilic drugs. SLNs have another advantage of allowing autoclave sterilization, an indispensible step in the formulation of ocular preparations. In this review a special attention has been given to the nature of lipids and surfactants commonly used for SLNs production. This article also reviews in detail the various fabrication methods, characterization, sterilization, and stabilization techniques for SLNs. In-vitro and in-vivo methods to study the drug release profile from SLNs have also been mentioned. A summary of previous studies involving the use of SLNs in ocular drug delivery is provided, along with a critical evaluation of SLNs as a potential colloidal ocular drug delivery system.

Sign in / Sign up

Export Citation Format

Share Document